

COMMENT

MEDICINE Don't deregulate: the market is useless at weeding out futile drugs **p.174**




MILITARY A history of the US agency behind the Internet and drones **p.176**

BIOLOGY Behind the scenes in the world of synthetic biology **p.178**

OBITUARY Peter Mansfield, physicist who developed MRI, remembered **p.180**

ERIK LUCERO



Google's cryostats reach temperatures of 10 millikelvin to run its quantum processors.

Commercialize early quantum technologies

Masoud Mohseni, Peter Read, Hartmut Neven and colleagues at Google's Quantum AI Laboratory set out investment opportunities on the road to the ultimate quantum machines.

From aspects of quantum entanglement to chemical reactions with large molecules, many features of the world cannot be described efficiently with conventional computers based on binary logic. The solution, as physicist Richard Feynman realized three decades ago¹, is to use quantum processors that adopt a blend of classical states simultaneously, as matter does. Many technical hurdles must be overcome for such quantum machines to be practical, however. These include noise control and improving the fidelity of operations acting on the quantum states that encode the information.

The quantum-computing community is channelling most of its efforts towards building the ultimate machine: a digital quantum computer that tolerates noise and errors, and that in principle can be applied to any problem. In theory, such a machine — which will need large processors comprising many quantum bits, or qubits — should be able to calculate faster than a conventional computer. Such capability is at least a decade away². Correcting for errors requires redundancy, and the number of qubits needed quickly mounts. For example, factorizing a 2,000-bit number in one day, a task believed to be intractable using classical computers³, would take 100 million qubits, even if individual quantum operations failed just once in every 10,000 operations. We have yet to assemble digital quantum processors with tens of qubits.

This conservative view of quantum computing gives the impression that investors will benefit only in the long term. We contend that short-term returns are possible with the small devices that will emerge within the next five years, even though these will lack full error correction.

A lack of theoretical guarantees need not preclude success. Heuristic 'hybrid' methods that blend quantum and classical approaches could be the foundation for powerful future applications. The recent success of neural networks in machine learning is a good example. In the 1990s, when the computing power required to train deep neural networks was unavailable, it was fashionable in the field to focus on 'convex' methods (based on functions with a clear minimum solution) that had a strong theoretical basis. Today, these methods are no match for deep learning. The underlying algorithms of neural networks ▶

► have hardly changed, yet impressive new performance milestones are being reached, thanks to ‘Moore’s law’.

Similarly, although there is no proof today that imperfect quantum machines can compute fast enough to solve practical problems, that may change. The scale, fidelity and controllability of analog and digital quantum hardware are improving steadily. We anticipate that, within a few years, well-controlled quantum systems may be able to perform certain tasks much faster than conventional computers based on CMOS (complementary metal oxide–semiconductor) technology.

Here we highlight three commercially viable uses for early quantum-computing devices: quantum simulation, quantum-assisted optimization and quantum sampling. Faster computing speeds in these areas would be commercially advantageous in sectors from artificial intelligence to finance and health care.

Capitalizing on imminent advances in quantum technologies requires that the discipline broadens its focus and that scientists work more closely with entrepreneurs. Hardware improvements are needed to make devices reliable and controllable enough to be commercialized. Heuristic quantum algorithms need to be developed that address practical problems within the current hardware limitations. As researchers working on quantum computing at Google, we plan to provide access to our quantum processors through cloud services to facilitate the development and benchmarking of quantum algorithms and applications across industries, delivering real benefit to society.

THREE PRIORITIES

If certain feasible technological improvements are achieved, we believe that emerging quantum processors have a good chance of carrying out the following classes of computational tasks and could become commercially valuable within a few years.

Quantum simulation. Modelling chemical reactions and materials is one of the most anticipated applications of quantum computing. Instead of spending years, and hundreds of millions of dollars, making and characterizing a handful of materials, researchers could study millions of candidates *in silico*. Whether the aim is stronger polymers for aeroplanes, more-effective catalytic converters for cars, more-efficient materials for solar cells, better pharmaceuticals or more-breathable fabrics, faster discovery pipelines will bring enormous value.

“Quantum-enhanced algorithms could improve patient diagnostics for health care”

Computational materials discovery is already a large industry. Quantum computers promise a radical transition: from the qualitative and descriptive to the quantitative and predictive. Chemical-reaction rates are extremely sensitive to molecular energies and span a range wider than classical methods can handle. If robust algorithms are developed, it might be possible to simulate important materials without the overhead of full quantum error correction⁴. For example, algorithms are already known (such as the ‘quantum variational eigensolver’ approach) that seem to be immune to qubit control errors.

A variety of business models could supply quantum simulators. Laboratories might pay a subscription for access. Computing companies could act as consultants. Some businesses might exchange equity in return for quantum-assisted breakthroughs that lead to innovative material developments.


Quantum-assisted optimization. A central and difficult computational task in all quantitative disciplines of physical and social sciences, and across industries, is optimization. Such problems are difficult to solve with conventional computers because algorithms can navigate only slowly through the mathematical landscape of possible solutions; good solutions may be hidden behind high barriers that are hard to overcome. The most general classical algorithms use statistical methods (such as thermal energy distributions) to ‘jump’ over these barriers. We believe that this type

of classical sampling could be enhanced by occasionally invoking quantum phenomena such as tunnelling (whereby quantum information is transmitted through barriers) to find rare but high-quality solutions.

For example, online recommendations and bidding strategies for advertisements use optimization algorithms to respond in the most effective way to consumers’ needs and changing markets. More-powerful protocols, based on a combination of quantum and classical solvers, could improve the quality of products and services in many industries. Logistics companies need to optimize their scheduling, planning and product distribution daily. Quantum-enhanced algorithms could improve patient diagnostics for health care. The quality of search or product recommendations for large information-technology companies such as ours, Microsoft, Amazon and Facebook could be enhanced.

Quantum sampling. Sampling from probability distributions is widely used in statistics and machine learning. In theory, ideal quantum circuits can sample from a larger set of probability distributions than classical circuits can in the same time. Our calculations show that, for relatively small circuits involving high-fidelity quantum gates, it will be possible to sample from probability distributions that are inaccessible classically, using a circuit of just 7×7 qubits in layers that are around 25 deep (ref. 5).

In fact, sampling from distributions with such a shallow quantum circuit is



The smaller of these chips, a 6-mm square, holds 6 qubits.

ERIK LUCERO

likely to constitute the first example of ‘quantum supremacy’. This term was coined by theoretical physicist John Preskill⁶ to describe the ability of a quantum processor to perform, in a short time, a well-defined mathematical task that even the largest classical supercomputers (such as China’s Sunway TaihuLight) would be unable to complete within any reasonable time frame. We predict that, in a few years, an experiment achieving quantum supremacy will be performed.

Among promising applications of quantum sampling are inference and pattern recognition in machine learning. To facilitate experimentation across academia and industry, we plan to offer access to the quantum hardware through a cloud-computing interface.


TECHNICAL HURDLES

Several technological challenges must be overcome for quantum computing to be commercialized. Quantum hardware needs to be scaled up to compete with classical hardware, which has been improving exponentially for decades. Qubits require quantum coherence, which leads to quantum entanglement, by analogy with how classical circuits require transistors with gain. Combining scaling and coherence is the big challenge of quantum systems engineering. It is fundamentally difficult because quantum information cannot be copied and subsystems are entangled, leading to design trade-offs that are global in nature.

We think that superconducting qubits are one of the most promising hardware platforms for quantum computers. Based on standard integrated-circuit and superconducting technologies, they are relatively easy to construct and control. And there are many possible designs that might suit different requirements for digital and analog quantum processors. High-fidelity systems of around ten qubits have been demonstrated, showing the feasibility of the engineering concepts.

New technologies are emerging that could aid scalability, such as superconducting bump bonds — a two-layer architecture for information-processing units and control circuits. Prototype ‘quantum annealers’ of about 1,000 qubits are already available commercially^{7,8}. (These are analog quantum processors that could find good-quality solutions for certain optimization tasks.)

Several improvements are required for today’s imperfect quantum devices to be practical. Shallow quantum circuits need higher gate fidelities and more stability to limit decoherence. Quantum-annealing hardware needs to be improved with respect to connectivity, control precision and coherence times, as well as having access to alternative annealing schedules⁹.



Radio-frequency and microwave electronics are used at Google to make scalable control hardware.

BUSINESS OPPORTUNITIES

A new technology can improve business in three ways: by increasing revenue, reducing costs or lowering investments in infrastructure. In the digital era, introducing a new technology has an exponential impact: even a 1% gain in product quality can help a company to achieve overwhelming growth in terms of user numbers or revenue¹⁰. This is the ‘superstar effect’, which assumes close competition, transparency and an efficient market.

If early quantum-computing devices can offer even a modest increase in computing speed or power, early adopters will reap the rewards. Rival companies would face high entry barriers to match the same quality of services and products, because few experts can write quantum algorithms, and businesses need time to tailor new algorithms. The markets that are most open to such disruptions are information-rich and digital, and involve business challenges that rely on many variables. Such markets include financial services, health care, logistics and data analytics.

Making a business case requires companies to examine demand and supply. Demand can be assessed as follows. First, identify the ‘minimal viable products’ — early quantum innovations with just enough core features to enter the market. Estimate whether the innovation solves an existing need (product–market fit), the time it would take to commercialize the product (speed to market) and the market’s response (business traction).

For example, encryption breaking — often portrayed in the media as a ‘killer application’

for digital quantum computers — does not score highly in terms of market fit. It will one day be superseded by cryptosystems that are immune to quantum attack. And most private enterprises are uninterested in breaking encryption systems. By contrast, portfolio optimization and risk management need immediate data feedback and could benefit from quantum-enhanced models¹¹. More efficient quantum-chemistry calculations would revolutionize the development of pharmaceuticals, catalytic converters, solar cells and fertilizers.

Quantum-assisted optimization and inference techniques could empower new machine-learning and artificial-intelligence systems. These could improve the management of renewable power generators, and of remote-sensing and early-warning systems. The techniques would also aid dynamic pricing for online goods and services, as well as warehouse automation and self-driving cars.

On the supply side, companies will distinguish themselves through the quality of their technology and teams. Pioneering quantum academics and entrepreneurs will have to work together. This will be challenging because academic incentives are often inconsistent with those of start-up cultures and industry.

Strategic partnerships can help businesses to stand out. To attract venture capitalists, the winning quantum products should have business models that require few assets, are low on manufacturing costs and clearly help customers to increase their revenues. Through the cloud, a company could benefit from using

existing data centres when applying classical solvers to simple problems, and invoke quantum processors when it matters.

WHAT NOW?

The field of quantum computing will soon achieve a historic milestone — quantum supremacy. It is still unknown whether application-related algorithms will be able to deliver big increases in speed using the sorts of processors that will soon be available. But when quantum hardware becomes sufficiently powerful, it will become possible to test this and develop new types of algorithms.

Over the next decade, academia, industry and national labs should work together to develop quantum simulation and quantum machine-learning algorithms. We plan to support such research by offering access to Google's quantum processors through cloud services to others that lack the necessary capital, expertise or infrastructure. ■

Masoud Mohseni is senior research scientist at Google Quantum Artificial Intelligence Laboratory in Venice, California; **Peter Read** is managing director at Vitruvian Partners in London; **Hartmut Neven** is director of engineering at Google Quantum Artificial Intelligence Laboratory in Venice, California; co-authors **Sergio Boixo**, **Vasil Denchev**, **Ryan Babbush**, **Austin Fowler**, **Vadim Smelyanskiy** and **John Martinis** are all part of Google's Quantum AI team.

e-mails: mohseni@google.com;
petermread@gmail.com;
neven@google.com

1. Feynman, R. *Int. J. Theor. Phys.* **21**, 467–488 (1982).
2. Touzalín, A. et al. *Quantum Manifesto: A New Area of Technology* (Quantum Information Processing and Communication in Europe, 2016); available at <http://go.nature.com/2im6rjr>
3. Fowler, A. G., Mariantoni, M., Martinis, J. M. & Cleland, A. N. *Phys. Rev. A* **86**, 032324 (2012).
4. Wecker, D., Hastings, M. B. & Troyer, M. *Phys. Rev. A* **92**, 042303 (2015).
5. Boixo, S. et al. Preprint at <https://arxiv.org/abs/1608.00263> (2016).
6. Preskill, J. in *The Theory of the Quantum World* (eds Gross, D., Henneaux, M. & Sevrin, A.) 63–80 (World Scientific, 2011).
7. Denchev, V. S. et al. *Phys. Rev. X* **6**, 031015 (2016).
8. Boixo, S. et al. *Nature Commun.* **7**, 10327 (2016).
9. Rams, M. M., Mohseni, M. & Del Campo, A. *New J. Phys.* **18**, 123034 (2016).
10. Brynjolfsson, E. & McAfee, A. *The Second Machine Age: Work, Progress, and Prosperity in a Time of Brilliant Technologies* (Norton, 2014).
11. Rosenberg, G. et al. *IEEE J. Sel. Top. Signal Process.* **10**, 1053–1060 (2016).

The authors declare competing financial interests: see go.nature.com/2rygdtf for details.



ILLUSTRATION BY DAVID PARKINS

Show drugs work before selling them

Regulation makes economic sense, argue Douglas Sipp, Christopher McCabe and John E. J. Rasko.

Under US President Donald Trump, defunct economic arguments about prescription drugs are coming to the fore. His advisers contend that today's system is a bad deal. They want to undo regulations that require companies to show that a medical product actually works before it is sold. The advisers argue that removing the burden of large, lengthy clinical trials will cut costs and reduce delays, and that the marketplace can

be trusted to sort good drugs from bad ones.

Although many have raised concerns about a Trump Food and Drug Administration (FDA; see, for example, *Nature* <http://doi.org/bz92>; 2017), few have debunked the economic arguments. Here we outline what the case for deregulation gets wrong. All nations should take note — weaker standards for entry of drugs onto the US market will harm health everywhere.

Knowledge of the history is important. The 1938 US Food, Drug, and Cosmetic Act required only that drug safety be demonstrated. In 1962, new legislation demanded that marketed drugs also go through well-controlled studies to test for therapeutic benefit. More than 1,000 medical products were subsequently withdrawn after reviews found little or no evidence of efficacy¹. The free market that existed before 1962 revealed no connection between a drug's ability to turn a profit and its clinical usefulness. The same is likely to be true of any future deregulated market.

MARKET FARGES

Economic arguments against the FDA's requirements for efficacy date back to at least the early 1970s. Originally these were advanced by libertarians and neoliberal economists at think tanks such as the American Enterprise Institute in Washington DC. Since the early 2000s, the Manhattan Institute for Policy Research in New York City has added its voice. Some economists posit that regulatory agencies are systematically biased towards excessive caution, and that the burden of testing a drug's efficacy before it comes to market outweighs the benefits.

They argue that 'bad' drugs can be identified quickly after they go on sale, whereas harms caused by the unrealized utility of 'good' drugs are often invisible (see go.nature.com/2hymtel). Such reasoning has led prominent economists, including Nobel prize-winners Milton Friedman, Gary Becker and Vernon Smith, to recommend that efficacy requirements be weakened or abandoned.

An overly stringent system will err by withholding or delaying safe and effective 'good' drugs from patients. Critics of existing regulations often point to the case of a treatment for Hunter syndrome — a rare, inherited degenerative disease in which the absence of a crucial enzyme can be fatal. Trials of the enzyme-replacement drug Elaprase (idursulfase) meant that, for a year, a group of children received a placebo instead of the drug that was eventually shown to be effective².

Conversely, a lax regulatory system will subject patients to 'bad' drugs that may be toxic. The iconic example is the more than 10,000 birth defects caused worldwide by the drug thalidomide, a late 1950s remedy for nausea during pregnancy. Even in the past dozen years, initially promising drugs, such as torcetrapib (for reducing cholesterol and heart-disease risk) and semagacestat (for improving cognition in people with Alzheimer's disease), were found to cause harm only after they had been tested in large, mandatory trials — effects that were not seen in the smaller trials³.

The most extreme proponents of deregulation argue that the market can serve as the sole arbiter of utility: if a medicine is selling well, it must be delivering value⁴. A more

THE GOOD, THE BAD AND THE USELESS

Allowed on market?	Drug is harmful ('bad' drug)	Drug is safe and beneficial ('good' drug)	Drug may be safe, but is useless ('futile' drug)
Yes	Patients at risk (toxicity)	Appropriate decision	False hope, wasted money
No	Appropriate decision	Patients lose out	Appropriate decision

moderate view is that reliable information on efficacy can be collected after a drug goes on sale, through uncontrolled observational studies and other post hoc analyses.

There is a third type of error that these arguments neglect (see 'The good, the bad and the useless'). Untested drugs can be reasonably safe but provide no benefit.

Unregulated markets are hopeless at sifting out these 'futile' drugs (witness the multi-billion-dollar industries in homeopathy and other pseudo-medicines), unlike the current system. In January 2017, the FDA released a report identifying 22 products that were initially promising but disappointed in

“Unregulated markets are hopeless at sifting out futile drugs.”

later-stage clinical trials: 14 for lack of efficacy, 1 for lack of safety, and 7 for both reasons⁵.

Futile drugs, even the non-toxic ones, cause real harms. They waste money for both patients and taxpayers. Marketing useless drugs wastes industry resources that could be used in developing effective therapies, squanders opportunities for patients to receive beneficial medical care, engenders false hope in miracle cures, and leads to cynicism about the value of research.

Some countries, including South Korea and Japan, have allowed cell biologics such as stem and immune cells onto the market without requiring them to show compelling evidence of efficacy. This might boost the domestic drug industry, but lowers the value of local health care. These products have not been authorized for sale in any other countries.

Europe should beware too. Lower drug-quality requirements in the large US market could make firms that adhere to the higher standards in the European Union less competitive.

NO FREE LUNCH

Arguments for deregulation fail to recognize that valuable information has a cost. Drug companies cannot afford to generate reliable evidence for efficacy unless their competitors are all held to the same high standards. Efficacy requirements level the playing field and ensure that the health sector receives the data needed to inform good therapeutic and economic decisions. The government, insurers, patients and others need to know whether medicines are likely to provide benefits. Patients and physicians must have access to reliable information to

make educated and ethical choices.

Rigorous clinical studies are still the best way to learn whether a drug works, and regulation is essential to ensure that these studies are conducted. Pre-specified endpoints, controls, randomization and blinding cannot be discarded without sacrificing actionable clinical information⁵.

Once a drug is on the market, it is hard to gather solid efficacy data. Blinding and randomization in clinical studies can be compromised when money changes hands and, historically, compliance with monitoring requirements has been poor. One analysis found that only 13% of post-market studies required by the FDA had been completed between 1990 and 1999 (see go.nature.com/2mayocv). And a survey of 20 drugs approved by the FDA in 2008 found that fewer than one-third of post-market study commitments had been fulfilled by 2013 (ref. 6). Marketed drugs are also unlikely to be withdrawn because of a lack of efficacy⁷.

The FDA's gatekeeper role makes the medical marketplace function. The economic benefits of good research and a healthier population will be lost without incentives to find truly effective drugs. ■

Douglas Sipp is a researcher at the RIKEN Center for Developmental Biology in Kobe, Japan, and visiting professor at Keio University School of Medicine and Global Research Institute, Tokyo. **Christopher McCabe** is a health economist at the University of Alberta, Edmonton, Canada. **John E. J. Rasko** is head of the Department of Cell and Molecular Therapies at Royal Prince Alfred Hospital in Sydney, Australia. e-mail: sipp@cdb.riken.jp

1. Junod, S. W. In *A Quick Guide to Clinical Trials* (eds Davies, M. & Kerimani, F.) 25–55 (Bioplan, 2008); available at <http://go.nature.com/2kjhny4>
2. Da Silva, E. M. K., Strufaldi, M. W. L., Andriolo, R. B. & Silva, L. A. *Cochrane Database Syst. Rev.* **2**, CD008185 (2016).
3. US Food and Drug Administration. *22 Case Studies Where Phase 2 and Phase 3 Trials had Divergent Results* (FDA, 2017); available at <http://go.nature.com/2mayug4>
4. Henderson, D. R. 'Markets Can Determine Drug Efficacy' *Forbes* (8 July 2009); available at <http://go.nature.com/2kbkzps>
5. Bothwell, L. E., Greene, J. A., Podolsky, S. H. & Jones, D. S. *N. Engl. J. Med.* **374**, 2175–2181 (2016).
6. Moore, T. J. & Furberg, C. D. *JAMA Intern. Med.* **174**, 90–95 (2014).
7. Sramshetty, V. B. et al. *Nucleic Acids Res.* **44**, D1080–D1086 (2016).

J.E.J.R. declares competing financial interests: see go.nature.com/2jct6ei for details.